Opening January 2027 in West Virginia, Ohio, and Kentucky. Join the waitlist →

How we measure success

Recovery programs should be judged on results, not promises. These are the numbers we track for every patient and will publish every year.

Time to first dose

Hours from first contact to prescription at the pharmacy. Target: under 24 hours for most patients.

Retention at 30, 90, and 180 days

The share of patients still in treatment. Retention is the single best predictor of survival in opioid use disorder.

Buprenorphine-positive screens

Whether patients are taking their medication as prescribed, the flip side of monitoring for other substances.

Overdoses and ED visits

Reported by patients and, with consent, from partners. The number we most want to drive to zero.

Counseling attendance

Sessions attended versus scheduled. Engagement, not perfection.

Social outcomes

Employment, stable housing, and resolved legal issues at 6 and 12 months, tracked by our recovery specialists.

Why we publish this

Payers, referral partners, and patients all deserve to know whether a program works. We report our numbers annually, compared with national benchmarks, and we report the bad ones too.

Our first outcomes report will be published after our first full year of operation.

The benchmark we're chasing

National retention in buprenorphine treatment at 6 months is commonly reported around 40–50 percent. Programs that combine medication, counseling, and practical support consistently do better. That combination is our whole model.

Want the numbers as a partner or payer?

Email sid@directionrecovery.com and we'll share what we have.

Call (386) 916-2117